Document is current

Article History

Received: 10 November 2022

Accepted: 22 September 2023

First Online: 13 November 2023

Declarations

:

: Ethics approval was obtained for the individual studies and informed consent was obtained from all subjects and/or their legal guardians. Upon consultation with the legal department, no further ethics approval was required. All methods were carried out according to relevant guidelines and regulations. The study [CitationRef removed] was approved by the UK National Health Service North and East Devon Research Ethics Committee. The study [CitationRef removed] was approved by the UK National Health Service South West Research Ethics Committee (09/H0206/43) and research governance approval was obtained from the local primary care trusts or health boards. The trial was conducted and reported in accordance with CONSORT guidelines. The study protocol of [CitationRef removed] was approved by institutional review boards at the Centre for Addiction and Mental Health (CAMH), Toronto, and St Joseph’s Healthcare, Hamilton. Participants provided written consent before engaging in any research activity. A patient organisation (Depressie Vereniging, Amersfoort, Netherlands) was involved in the design of study [CitationRef removed], development of prevention strategies for relapse, participant recruitment, and in discussing the interpretation of the results. An independent medical ethics committee for all included sites (METIGG) approved the DRD trial protocol. The trial was done in accordance with CONSORT guidelines. All participants provided written informed consent.

: Not applicable.

: The authors declare no competing interests.